📇 Rhumatologue ·
Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
1 raison identifiée
Référence presse grand public
Cité 10 fois dans les médias — pédagogie reconnue
✨ Génération du profil synthétique IA en cours…
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Source : Google News (recherche par nom complet — homonymes possibles, vérifier le contenu).
📰 Le Journal du Centre · 09/02/2026
<a href="https://news.google.com/rss/articles/CBMi7gFBVV95cUxNNS0xc2psQjNLRTE4Ym9UeGpQTDZDOHZZcDgtZmtRZkVyQjNEc3ZlNHhaT3lxalltenVTWWEybHBYd0RiZHJhNE1iOVd2b2NiemZrdVQtTXh6OC01cUxmdDBPeFF5bXlKQ29oMlRWdlFhSXBVZzJoeVc1NDhHNlBibDdwbVpXN2hKa0JZSDZnV3RTUUExYnVlb0hlN2xDdzFyLW54NnQ4bVg3WHlnOWlaRnd5UFJiWmhPTz
📰 Ouest-France · 12/06/2022
<a href="https://news.google.com/rss/articles/CBMi9wFBVV95cUxORnk3OW9LcE9kekg0eEtJYjJvWk1xQnJIYll0UDhjTEx1ODZYSHQ0LUF4bG44MWxGQUtGbzljeHI4YnNWWVpSVl96QjRkUnNlbFpiNHZOQVhOckpzN05RZExwX0NKSW9rTVFKS0c2Tk9QTW5aSnJsc1ZoRXl6WUdXcVRQbm5aWkVyUHB6SzNxaDhBcVNZN0dkTzBIMWJlOFZxalpvRDFwYUI5b2F5UV9oeTBzQTJ6NmNfbU
📰 ici.fr · 14/06/2022
<a href="https://news.google.com/rss/articles/CBMi1gFBVV95cUxNa25WV3JpV0ZIWVlQRWwyd1YyWFI1Uk5PdDZNSHpuUFpoSWN1a1NzcE9BZUEzcm9VTWFuVVA1Z2JpUEFLQmhnYzctSmtkMmNkYVpBdy1LNGlXYzlwNkxqUTg4dExjNFhWemJnRHpTaWZDdG1JeFJyWFE4SVAzMW9hYkN0UDBrQjVodVRISk1tUE13UkNCalhSQ1dLMVJSVm9oaGlfWmVYMmEtaWJ3dmp4c3VZVWpXTnREWV
📰 Europe 1 · 26/01/2023
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxPeVdVNzB4S3pJWWprTTBiZlJJVjA0MmFWeU84Yjd2ZE4wa1V2ejlGYlJhakZRYmF1UTRKMkhGUzRoNUdiTC1XcmRCaXVpdXotM2VwNnJ5aE1xNEIzMFFTa0g5djIteGhEOEpzUTdZTnBKRldQcENnYXFTNEItemhwS3ZpUF9vSWtNSWF2SUNUTWRkRm1RbFlhQlhsMXgxd9IBowFBVV95cUxOeWlzNG9DUGNxWURXN2ZDb0
📰 Le Journal du Centre · 07/11/2024
<a href="https://news.google.com/rss/articles/CBMimgJBVV95cUxQTzA0TDgyVXNNMWhTYlpCY25ySFNnTUtmVC1najFQR2hRd2pzTld6UmVwc1I5cnJ5X2U0aWRzWEpSRVFFaHN6ZFU2TTR2b3RoSVJxRkhFRXY1Mlg5SFZ1aHJpUlFBRWRpaDdzY08tZzJoaGZ6SHRnTGk4alZsTkRYaDNBSUxYbVZMVXRxaVgtU1NwUXN6d2VjdzNfUmpRUjh4ZTF5MjJSWmF2TEdXWGszc1lPb3JvYVlSMU
📰 Le Journal du Centre · 12/10/2023
<a href="https://news.google.com/rss/articles/CBMi3wFBVV95cUxPTHdMdU4xaTRzSktfc2hWLUlHR1o4SGhvUTVzamRzczE4MEktS1RBQVBvMUIzak81NnpLbTAzeTFNelQ1SUlob2VyT1M3ZEJyZG5Fbk5Nc3RUQzZEakhVR2NiY2gxb1QycjQ1bm95UFZnWlhrY1I3bXlReDdDd2JjbUVXYjdsRmc4WGtJV2dpc1FzRktDY2lJcmU4dVdWMFlfU3J4OENUN19JeGdzSjRQbHBlaVdKU2RfSU
📰 Le Journal du Centre · 12/12/2024
<a href="https://news.google.com/rss/articles/CBMiwwFBVV95cUxNNExWeWhJSG82NE9WVG80SXFGcC1HaGFJVWFBZG9MWXYwTU9wQU5wNmZlcGRiNVljcS1iWVNYXzl6bGw2Y1ZsVl9Xa2NGS0RmT1FmdTcydm9VUWFBR0Q5ZWFzQm5GMDh2U0tBT1ViZFJSUmxuQkc4R1B0LWhVeDZxVTNPc3pKVXdfLWJ2d2E1d1o2aGZ6THgxdGFScjdPQWlBb2RFRWhMWWNIVmpnbERobVc0aTljTmp4Tk
📰 Le Journal du Centre · 07/01/2022
<a href="https://news.google.com/rss/articles/CBMi3wFBVV95cUxNaW91dENyTDk1alE0NkNmOWEyU2w3Sno0LUdwNzVtSmVRbUJCbnFzTVVKZmdtRUFQSUxiV28xbk5CNnJ2aWF4NnNaQVNydkF5M3k5RjJQcm5rSk84OTVBeFAzalFNa3lSa1RGLVpRZEx1WEduaUR2WWNhTkYxb1puOVlhekFsZTBiNXNYYVVtU29XZFdPamczNXAyeVc5M0tMVVN2MDZDRkFCWWMxdmNpMGQ1SEEyYTJJNG
📰 Le Journal du Centre · 08/04/2022
<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxOZXVCVW9rRl9jbVp0RVRRb0NUamVRcFRFazB0SUJwYmQ3X1ZmMXFXQ2hZT3ZCYnJxMFI4ZUt1YmVXSk5kR1ExTnlPNjlDNWNjQU5VckhEWVR2cjZrYXk3V3o5TXV2MkxzVHUyOXI4cEZubUVISzBEeWY5dUVLQlc5bG45NXVPQmhTTFlHejZhNzVDcE16TDhHdklMLVVFZzZGaTNqM2JPOFZBLVNa?oc=5" target="_bl
📰 Le Journal du Centre · 09/12/2017
<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxOTmhLMEx6ZlQ0QUZVMi1EQ3FSbUQ5OWl1dW14TWxRVUVwOUZYVnRGMFJOM1ZLejlCc1pzWmt2akNFQmgtajFfM1lHbXZxUTFxMUk5LTYyQVRBcU94N2lvc1RnUHltUF9WcEtRZktLWmJneDhVRHVHM1I1RFlDMmRSLVRvT2lVRmRBUmJ4UzR1YktRMjZuWmFrdEhUYUNRenpZZDN6d2s4RHdxNmFxQ1I1M3VMbDZ6WEQ0TE
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2020
Abstract Background Belatacept (bela) rescue therapy seems to be a valuable option for calcineurin inhibitor chronic toxicity in kidney transplantation. Nevertheless, the risk of infection associated with bela is not well reported. Methods We report the rate of opportunistic infections (OPI) after a switch to bela in a multicentric cohort of 280 kidney transplant patients. Results Forty-two OPI occurred in 34 patients (12.1%), on average 10.8 ± 11.3 months after the switch. With a cumulative exposure of 5128 months of bela treatment, we found an incidence of 0.008 OPI/month of exposure, and 9.8 OPI/100 person-years. The most common OPI was cytomegalovirus (CMV) disease in 18/42 OPI (42.9%) and pneumocystis pneumonia in 12/42 OPI (28.6%). Two patients presented a progressive multifocal leucoencephalopathy and two patients developed a cerebral Epstein–Barr virus-induced post-transplant lymphoproliferative disease. OPI led to death in 9/34 patients (26.5%) and graft failure in 4/34 patients (11.8%). In multivariate analysis, estimated glomerular filtration rate &lt;25/mL/min/1.73 m2 on the day of the switch and the use of immunosuppressive agents before transplantation were associated with the occurrence of OPI. We found a higher rate of infection-related hospitalization (24.1 versus 12.3/100 person-years, P = 0.0007) and also a higher rate of OPI (13.2 versus 6.7/100 person-years, P = 0.005) in the early conversion group (within 6 months). Conclusions The risk of OPI is significant post-conversion to bela and may require additional monitoring and prophylactic therapy, particularly regarding pneumocystis pneumonia and CMV disease. These data need to be confirmed in a larger case–control study.
Bone marrow transplantation · 2023
AbstractMucopolysaccharidosis type I-H (MPS I-H) is a rare lysosomal storage disorder caused by α-L-Iduronidase deficiency. Early haematopoietic stem cell transplantation (HSCT) is the sole available therapeutic option to preserve neurocognitive functions. We report long-term follow-up (median 9 years, interquartile range 8–16.5) for 51 MPS I-H patients who underwent HSCT between 1986 and 2018 in France. 4 patients died from complications of HSCT and one from disease progression. Complete chimerism and normal α-L-Iduronidase activity were obtained in 84% and 71% of patients respectively. No difference of outcomes was observed between bone marrow and cord blood stem cell sources. All patients acquired independent walking and 91% and 78% acquired intelligible language or reading and writing. Intelligence Quotient evaluation (n = 23) showed that 69% had IQ ≥ 70 at last follow-up. 58% of patients had normal or remedial schooling and 62% of the 13 adults had good socio-professional insertion. Skeletal dysplasia as well as vision and hearing impairments progressed despite HSCT, with significant disability. These results provide a long-term assessment of HSCT efficacy in MPS I-H and could be useful in the evaluation of novel promising treatments such as gene therapy.
Transplant international : official journal of the European Society for Organ Transplantation · 2024
After kidney transplantation, conversion to belatacept is a promising alternative in patients with poor graft function or intolerance to calcineurin inhibitors. The risk of acute rejection has not been well described under these conditions. Here we present a retrospective multicenter study investigating the occurrence of acute rejection after conversion in 901 patients (2011–2021). The incidence of cellular and humoral rejection was 5.2% and 0.9%, respectively. T-cell mediated rejection (TCMR) occurred after a median of 2.6 months after conversion. Out of 47 patients with TCMR, death-censored graft survival was 70.1%, 55.1% and 50.8% at 1 year, 3 years and 5 years post-rejection, respectively. Eight patients died after rejection, mainly from infectious diseases. We compared these 47 patients with a cohort of kidney transplant recipients who were converted to belatacept between 2011 and 2017 and did not develop rejection (n = 238). In multivariate analysis, shorter time between KT and conversion, and the absence of anti-thymocyte globulin induction after KT were associated with the occurrence of TCMR after belatacept conversion. The occurrence of rejection after conversion to belatacept appeared to be less frequent than with de novo use. Nevertheless, the risk of graft loss could be significant in patients with already low renal function.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Transplant international : official journal of the European Society for Organ Transplantation · 2024 · Journal Article
Bertrand D, Chavarot N, Olagne J, Greze C, et al.
Bone marrow transplantation · 2023 · Journal Article
Gardin A, Castelle M, Pichard S, Cano A, et al.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2020 · Journal Article
Bertrand D, Chavarot N, Gatault P, Garrouste C, et al.